---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-040755"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2025-03-18T23:59:59+00:00"
generated_at: "2026-05-24T13:59:57.460006+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Korro Bio reports FY2024 net loss $83.6M; cash $163.1M; KRRO-110 interim readout H2 2025

## Summary
- Net loss $83.6M (vs $81.2M in 2023); R&D expenses $63.6M; G&A $30.5M.
- Cash, cash equivalents $163.1M; runway into H2 2026 expected to fund KRRO-110 trial.
- KRRO-110 Phase 1/2a REWRITE trial: completed dosing first two cohorts; no SAEs; interim data H2 2025.
- FDA granted Orphan Drug Designation for KRRO-110 for AATD.
- Collaboration revenue $2.3M from Novo Nordisk partnership; second development candidate expected end 2025.

## SEC filing metadata
- accession: 0000950170-25-040755
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2025-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000095017025040755/0000950170-25-040755-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000095017025040755/krro-20250318.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-040755
- JSON: https://secwatch.observer/filing/0000950170-25-040755.json
- Plain text: https://secwatch.observer/filing/0000950170-25-040755.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.